AbbVie (ABBV) reportedly in talks to buy Revolution Medicines (RVMD), according to WSJ

AbbVie's potential acquisition of Revolution Medicines highlights the company's focus on expanding its oncology portfolio.

Newsquawk StaffPublished On the live feed at , 20 minutes before this page
Newsquawk headlinesUTC

Q4 GDP data has been rescheduled for Feb 20th, October and November Personal Income and PCE to be released January 22nd

US Treasury is implementing Trump's no tax on American car loan interest, via Treasury Secretary Bessent on X

AbbVie (ABBV) reportedly in talks to buy Revolution Medicines (RVMD), according to WSJ

CRUDE WRAP: WTI (G6) SETTLES USD 1.14 LOWER AT 55.99/BBL; BRENT (H6) SETTLES USD 0.74 LOWER AT USD 59.96/BBL

Arm (ARM) launches Physical AI division to expand in robotics market

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This move could be strategically sound if it enhances AbbVie’s competitive position in the biotech sector. Investors will want to assess the terms of the deal and any regulatory hurdles that may arise, as they could impact similar M&A activity in the industry.

Related headlines

The whole workspace, free to try.

Try it free